Beam Therapeutics Inc.
Simply Wall St reports Beam Therapeutics (NASDAQ:BEAM) missed Q2 expectations, with revenue of about $490k, 97% below forecasts, and a loss of $1.18 per share, 7.5% worse than modeled. For 2026, analysts cut revenue to $53.8m (down from $78.9m) and forecast EPS loss rising to $4.40. Consensus price target stays near $52.15.
Beam Therapeutics (BEAM) reported a wider-than-expected Q2 2026 loss of $1.18 per share versus a $1.00 consensus loss. Revenue fell to $0.5 million, below a $30 million estimate, from $8.5 million a year earlier. Cash and securities were about $1.2 billion, supporting operations into mid-2029. Pipeline updates include risto-cel and BEAM-302 accelerated-approval plans.
Beam Therapeutics reported 2Q 2026 results in its 10-Q. Revenue was $0.5M, down from $8.5M a year earlier. Net loss attributable to Beam was $(122.7)M versus $(102.1)M, and diluted EPS was $(1.18) versus $(1.00). The company said BEACON risto-cel dosing is complete and a BLA is targeted for year-end 2026.
Over the past 7 days, alphai's AI scored 4 news stories mentioning BEAM (Beam Therapeutics Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 3 bearish.
Recent BEAM coverage spans financial news, earnings and insider activity.
In the last 30 days, BEAM insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($429K). The most active reporter was Simon Amy, Chief Medical Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Street expectations for BEAM’s 2026 top line deteriorated sharply after the earnings miss, while EPS-loss outlook was largely unchanged.
The print is a clear near-term earnings disappointment, while the main offset is continued progress toward risto-cel BLA and BEAM-302 accelerated-approval pathway.
The 10-Q provides fresh financial datapoints and reiterates clinical and manufacturing milestones, which can shift near-term risk perception and funding runway expectations.
Near-term catalysts cluster around BEAM-302 pivotal enrollment and ERS late-breaking data selection, plus BEAM-304 IND clearance and risto-cel dosing completion.
New, decision-relevant timeline catalysts for Beam’s base-editing pipeline (BEAM-302, risto-cel) and cash runway through mid-2029.
alphai scores every news story that mentions BEAM with an AI model for sentiment and relevance, and aggregates insider trades from Beam Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Simply Wall St reports Beam Therapeutics (NASDAQ:BEAM) missed Q2 expectations, with revenue of about $490k, 97% below forecasts, and a loss of $1.18 per share, 7.5% worse than modeled. For 2026, analysts cut revenue to $53.8m (down from $78.9m) and forecast EPS loss rising to $4.40. Consensus price target stays near $52.15.
6 min readBeam Therapeutics (BEAM) reported a wider-than-expected Q2 2026 loss of $1.18 per share versus a $1.00 consensus loss. Revenue fell to $0.5 million, below a $30 million estimate, from $8.5 million a year earlier. Cash and securities were about $1.2 billion, supporting operations into mid-2029. Pipeline updates include risto-cel and BEAM-302 accelerated-approval plans.
6 min readBeam Therapeutics reported 2Q 2026 results in its 10-Q. Revenue was $0.5M, down from $8.5M a year earlier. Net loss attributable to Beam was $(122.7)M versus $(102.1)M, and diluted EPS was $(1.18) versus $(1.00). The company said BEACON risto-cel dosing is complete and a BLA is targeted for year-end 2026.
1 min readBeam Therapeutics Inc. (BEAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Updated BEAM-302 Phase 1/2 Clinical Data Se
4 min readArk Invest’s Cathie Wood has continued buying Beam Therapeutics (BEAM), with the most recent purchases last week totaling about $4 million. Wood’s stake is reported at over $300 million. Beam is advancing base-editing programs, including BEAM-302 for alpha-1 antitrypsin deficiency and risto-cel for sickle cell, with FDA filings expected by end-2026. Beam reported $1.21B cash at Q1 and a net loss of $94.3M.
6 min readBank of America Securities analyst Alec Stranahan reaffirmed a Buy rating on Beam Therapeutics (NASDAQ:BEAM) after Prime Medicine’s arbitration resolution. Stranahan set a $47 target price, citing limited impact on Beam because the outcome relates to Prime’s PM647. He said Beam’s focus remains on BEAM-302 biomarker data and execution for alpha-1 antitrypsin deficiency, with Prime viewed as a distant threat.
3 min readPrime Medicine said it won a dispute with Beam Therapeutics over gene-editing technology rights related to AATD. Prime expects to start an AATD clinical trial this quarter, and its stock rose about 11% while Beam fell about 2%. Beam said it disagrees and may pursue further action, according to company statements.
7 min readBeam Therapeutics shares fell about 5% after an arbitration tribunal ruled for Prime Medicine in a dispute over rights to PM647, an investigational gene editing therapy for Alpha-1 Antitrypsin Deficiency. The tribunal said PM647 is within Prime’s licensed “Field” under a 2019 agreement. The move followed a recent 52-week high and an H.C. Wainwright Buy rating with an $80 target, while broader equities declined on renewed geopolitical risk.
3 min readPrime Medicine (NASDAQ:PRME) shares rose 11.3% after a binding arbitration ruling against Beam Therapeutics (NASDAQ:BEAM) over development rights to PM647. The tribunal said PM647 is within Prime’s defined “Field” under a 2019 agreement, finding no breach and no monetary damages owed. Prime plans to file an IND/CTA in Q3 2026 and expects initial data in 2027.
4 min readEvans John M. (CEO) sold 50,000 shares of Beam Therapeutics Inc. (BEAM) at an average of $34.90 ($34.26–$35.91, $1.75M total) across 4 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
2 min read
